Welcome to our dedicated page for CEL SCI SEC filings (Ticker: CVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CEL SCI's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CEL SCI's regulatory disclosures and financial reporting.
Cel-Sci Corp (CVM) Form 4: Senior Vice President John Cipriano received 7,500 stock options on 07/28/25 at an exercise price of $8.20, expiring 07/27/35. Vesting occurs in three equal annual tranches beginning one year from grant. No common shares were bought or sold; the filing records an “A” code equity award rather than an open-market transaction. After the grant, Cipriano holds 38,008 derivative securities. The award is typical incentive compensation with negligible near-term cash flow or dilution impact for shareholders.
CEL-SCI Corp (CVM) – Form 4 insider transaction
Director Robert E. Watson bought 2,919 restricted shares of CEL-SCI on 25-Jul-2025 at $6.85 (prior day’s close), a cash outlay of roughly $20k. Following the purchase, Watson’s direct holdings increased to 3,733 shares. No derivative securities were involved and the filing shows the transaction was made directly with the company, suggesting an equity-based compensation or voluntary open-market style purchase rather than option exercise or planned sale. The filing does not reference any concurrent sales, options, or changes in indirect ownership.
The transaction is modest relative to CEL-SCI’s market capitalization and daily trading volume, but insider buying—especially by a board member—can signal personal confidence in the company’s prospects and may be viewed positively by investors monitoring governance alignment.